Humphrey John M, Mpofu Philani, Pettit April C, Musick Beverly, Carter E Jane, Messou Eugène, Marcy Olivier, Crabtree-Ramirez Brenda, Yotebieng Marcel, Anastos Kathryn, Sterling Timothy R, Yiannoutsos Constantin, Diero Lameck, Wools-Kaloustian Kara
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Biostatistics, Indiana University Fairbanks School of Public Health, Indianapolis, Indiana, USA.
Open Forum Infect Dis. 2020 Jan 10;7(1):ofaa006. doi: 10.1093/ofid/ofaa006. eCollection 2020 Jan.
In resource-constrained settings, many people with HIV (PWH) are treated for tuberculosis (TB) without bacteriologic testing. Their mortality compared with those with bacteriologic testing is uncertain.
We conducted an observational cohort study among PWH ≥15 years of age initiating TB treatment at sites affiliated with 4 International epidemiology Databases to Evaluate AIDS consortium regions from 2012 to 2014: Caribbean, Central and South America, and Central, East, and West Africa. The exposure of interest was the TB bacteriologic test status at TB treatment initiation: positive, negative, or no test result. The hazard of death in the 12 months after TB treatment initiation was estimated using a Cox proportional hazard model. Missing covariate values were multiply imputed.
In 2091 PWH, median age 36 years, 53% had CD4 counts ≤200 cells/mm, and 52% were on antiretroviral therapy (ART) at TB treatment initiation. The adjusted hazard of death was higher in patients with no test compared with those with positive test results (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.08-2.26). The hazard of death was also higher among those with negative compared with positive tests but was not statistically significant (HR, 1.28; 95% CI, 0.91-1.81). Being on ART, having a higher CD4 count, and tertiary facility level were associated with a lower hazard for death.
There was some evidence that PWH treated for TB with no bacteriologic test results were at higher risk of death than those with positive tests. Research is needed to understand the causes of death in PWH treated for TB without bacteriologic testing.
在资源有限的环境中,许多艾滋病毒感染者在未进行细菌学检测的情况下接受结核病治疗。与进行细菌学检测的患者相比,他们的死亡率尚不确定。
我们在2012年至2014年期间,对年龄≥15岁、在4个国际艾滋病流行病学数据库评估艾滋病联盟地区所属地点开始接受结核病治疗的艾滋病毒感染者进行了一项观察性队列研究,这些地区包括加勒比地区、中美洲和南美洲以及中非、东非和西非。感兴趣的暴露因素是开始结核病治疗时的结核细菌学检测状态:阳性、阴性或无检测结果。使用Cox比例风险模型估计开始结核病治疗后12个月内的死亡风险。对缺失的协变量值进行多次插补。
在2091名艾滋病毒感染者中,中位年龄为36岁,53%的患者CD4细胞计数≤200个/mm,52%的患者在开始结核病治疗时正在接受抗逆转录病毒治疗(ART)。与检测结果为阳性的患者相比,未进行检测的患者调整后的死亡风险更高(风险比[HR],1.56;95%置信区间[CI],1.08 - 2.26)。检测结果为阴性的患者与阳性患者相比,死亡风险也更高,但无统计学意义(HR,1.28;95%CI,0.91 - 1.81)。接受ART治疗、CD4细胞计数较高以及三级医疗机构水平与较低的死亡风险相关。
有证据表明,在未进行细菌学检测的情况下接受结核病治疗的艾滋病毒感染者的死亡风险高于检测结果为阳性的患者。需要开展研究以了解在未进行细菌学检测的情况下接受结核病治疗的艾滋病毒感染者的死亡原因。